.png "Guest Editorial: Bempedoic Acid Therapy for Patients with Statin Intolerance | National Lipid Association Online")
Guest Editorial: Bempedoic Acid Therapy for Patients with Statin Intolerance | National Lipid Association Online
Summary of dyslipidemia phase III trials with bempedoic acid. | Download Scientific Diagram
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials - Journal of Clinical Lipidology
Defining the role of bempedoic acid in lowering low-density lipoprotein cholesterol
Efficacy and safety of bempedoic acid alone or combining with other lipid-lowering therapies in hypercholesterolemic patients: a meta-analysis of randomized controlled trials | BMC Pharmacology and Toxicology | Full Text
Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort - Clinical Therapeutics
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial - Atherosclerosis
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance | Journal of the American Heart Association
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol | NEJM
CLEAR Serenity Trial: More Clarity for the Future of Bempedoic Acid in Patients Unable to Take Statins? | Journal of the American Heart Association
Esperion Therapeutics: Does The Rally 'Have Legs'? (NASDAQ:ESPR) | Seeking Alpha
Esperion Presents Pooled Phase 3 Data | Biotech Investments
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials - Journal of Clinical Lipidology
American College of Cardiology på Twitter: "The CLEAR Wisdom trial showed that bempedoic acid is safe and effective in reducing LDL-C compared with placebo among patients with #ASCVD or heterogeneous FH on
PDF) Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Bempedoic Acid for Heterozygous Familial Hypercholesterolemi | DDDT
ESC 2018 – Esperion aims to ease safety fears, but bigger test awaits | Evaluate
Role of Bempedoic Acid in Clinical Practice | SpringerLink
New cardiovascular prevention guidelines: How to optimally manage dyslipidaemia and cardiovascular risk in 2021 in patients needing secondary prevention? - Atherosclerosis
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance | Journal of the American Heart Association
32614-0.fp.png "BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS | Journal of the American College of Cardiology")
BEMPEDOIC ACID EFFICACY AND SAFETY IN HIGH CVD RISK PATIENTS TREATED WITH OR WITHOUT EZETIMIBE: POOLED ANALYSIS OF 4 PHASE 3 CLINICAL TRIALS | Journal of the American College of Cardiology
EX-99.1 2 a18-12501_2ex99d1.htm EX-99.1 Exhibit 99.1 Media Contact: Elliot Fox W2O Group 212.257.6724 efox@w2ogroup.com Investor Contact: Audrey Gross W2O Group 212.301.7214 agross@w2ogroup.com Esperion Announces Positive Top-Line ...
Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial - Journal of ...
Frontiers | Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol | Cardiovascular Medicine
Guest Editorial: Bempedoic Acid Therapy for Patients with Statin Intolerance | National Lipid Association Online
